Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7113506 | 0.76 | — | — | |
| SCHEMBL28241502 | 0.72 | IDO1 (0.46) | — | |
| SCHEMBL3628858 | 0.71 | — | — | |
| SCHEMBL2050240 | 0.71 | — | — | |
| SCHEMBL15190357 | 0.71 | — | — | |
| SCHEMBL28863350 | 0.71 | IDO1 (0.50) | — | |
| Hydrochloric Acid SCHEMBL28226758 | 0.70 | — | — | |
| SCHEMBL28863469 | 0.69 | IDO1 (0.53) | — | |
| SCHEMBL29961836 | 0.69 | BRS3 (0.30) | — | |
| SCHEMBL23069188 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11197858-B2 | Substituted amines for treating cardiac diseases | CARDURION PHARMACEUTICALS, LLC (US) | 2021-12-14 | — | — | US | disclosed |
| US-10543212-B2 | Substituted amines for treating cardiac diseases | CARDURION PHARMACEUTICALS, LLC (US) | 2020-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11197858-B2 | Substituted amines for treating cardiac diseases | TNNI3, CALM1, CAMK2G | ADORA2A 709/4885 |
| US-10543212-B2 | Substituted amines for treating cardiac diseases | TNNI3, CALM1, CAMK2G | ADORA2A 709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.